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Abstract 
Background: Animal venoms are large, complex libraries of bioactive, disulphide-rich peptides. These peptides, 
and their novel biological activities, are of increasing pharmacological and therapeutic importance. However, recom-
binant expression of venom peptides in Escherichia coli remains difficult due to the significant number of cysteine 
residues requiring effective post-translational processing. There is also an urgent need to develop high-throughput 
recombinant protocols applicable to the production of reticulated peptides to enable efficient screening of their drug 
potential. Here, a comprehensive study was developed to investigate how synthetic gene design, choice of fusion tag, 
compartment of expression, tag removal conditions and protease recognition site affect levels of solubility of oxidized 
venom peptides produced in E. coli.
Results: The data revealed that expression of venom peptides imposes significant pressure on cysteine codon selec-
tion. DsbC was the best fusion tag for venom peptide expression, in particular when the fusion was directed to the 
bacterial periplasm. While the redox activity of DsbC was not essential to maximize expression of recombinant fusion 
proteins, redox activity did lead to higher levels of correctly folded target peptides. With the exception of proline, the 
canonical TEV protease recognition site tolerated all other residues at its C-terminus, confirming that no non-native 
residues, which might affect activity, need to be incorporated at the N-terminus of recombinant peptides for tag 
removal.
Conclusions: This study reveals that E. coli is a convenient heterologous host for the expression of soluble and func-
tional venom peptides. Using the optimal construct design, a large and diverse range of animal venom peptides were 
produced in the µM scale. These results open up new possibilities for the high-throughput production of recombi-
nant disulphide-rich peptides in E. coli.
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Background
Animal venoms comprise an arsenal of dozens to hun-
dreds of structurally diverse disulphide-rich peptides that 
possess important pharmacological, therapeutic and bio-
technological value. Considering the number of animal 
species that produce venoms and the average number 
of peptides per venom, the library of naturally evolved 
venom peptides may encompass millions of different 
molecules. These highly stable disulphide-reticulated 
peptides display formidable affinity and selectivity while 
presenting low immunogenicity making them attrac-
tive candidates for the development of novel therapeu-
tics [1]. In general venom peptides target a variety of cell 
surface receptors, such as ion channels, and interaction 
with their molecular ligands dramatically affects cellular 
function [2]. Venom peptides generally contain between 
20 and 120 residues and include up to eight disulphide 
bonds that are critical for both biological activity and 
stability. Thus, the correct oxidation of cysteine resi-
dues leading to proper disulphide pairing is required for 
folding and functional activity. Unfortunately, the use of 
venom peptides as therapeutic or biotechnological mol-
ecules is still hampered by the difficulty to produce native 
and active proteins in sufficient amounts [3].
De novo gene synthesis is the most convenient route 
to obtain genes for recombinant expression. This is par-
ticularly true for genes encoding venom peptides, as 
the sequence information from genomic and transcrip-
tomic projects is usually not available as palpable DNA. 
Designing a gene to express a protein requires selecting 
from an enormous number of possible DNA sequences 
[4]. In addition, effective gene design may be affected by 
gene family. For example, a high percentage of cysteine 
residues in venom peptides may impose particular con-
straints in levels of gene expression and these remain to 
be uncovered for the particular case of genes encoding 
animal venom peptides. Usually, gene design involves 
selecting a codon usage that maximizes levels of expres-
sion based on the codon bias of a subset of highly-
expressed native host genes [5, 6]. Expression may also 
be impaired by a strong mRNA secondary structure near 
the translational start site, inadequate GC content or 
presence of unwanted regulatory sequences recognized 
by the cellular expression machinery [7]. Although dif-
ferent studies have analysed how genes can be designed 
efficiently, there is still no information about the major 
factors affecting expression of genes encoding reticulated 
peptides in heterologous hosts.
Escherichia coli is a highly robust bioreactor for heter-
ologous protein expression. Several high throughput plat-
forms have been developed using this bacterium [8, 9]. E. 
coli is particularly adequate to generate large libraries of 
recombinant proteins to apply to functional screens with 
biomedical and biotechnological relevance. However, 
production of disulphide-bonded proteins in bacteria is 
hampered by the lack of an effective post-translational 
system. Thus, in E. coli reticulated peptides are especially 
prone to aggregation or degradation due to possible mis-
pairing of cysteine residues or undesirable intermolecular 
disulphide bonds. In addition, gene expression in bacteria 
is regulated by strong promoters, leading to the accumu-
lation of recombinant proteins as insoluble aggregates or 
inclusion bodies. Different technologies have been devel-
oped to promote the correct oxidation of cysteine resi-
dues in recombinant proteins expressed in bacteria [10]. 
Exporting the proteins to the E. coli oxidative periplasm 
is a well-established strategy although levels of recom-
binant protein can be limited by protein export [11]. For 
successful expression, two challenges must be met; (i) the 
peptide of interest must be maintained in a soluble state, 
and (ii) the correct disulphide bonds must be formed 
within the peptide. Recently some fusion tags displaying 
not only a solubilizing effect but also redox properties, 
such as DsbA and DsbC, were described by our group to 
enhance the solubility of venom peptides while promot-
ing correct disulphide bond formation [8, 11]. However, 
the most effective high-throughput-compatible strategy 
to express a wide panel of correctly folded venom pep-
tides in E. coli remains to be established.
Fusion tags are indispensable tools for protein expres-
sion and purification in bacteria [12]. However, pres-
ence of a fusion tag may interfere with protein function 
and their removal from the target protein is desirable. 
Tobacco etch virus (TEV) protease [13] is one of the most 
popular enzymes used to remove fusion tags from recom-
binant proteins due to the stringent sequence specificity 
it displays. However, TEV protease may require a Gly or 
Ser residue at the C-terminus (P1′ position) of its recog-
nition site [14], leaving a non-native Ser or Gly residue at 
the N-terminus of the target protein after tag removal. In 
the specific case of venom peptides it is well known that 
the N-terminal part of the peptide can contribute to the 
pharmacophore involved in receptor binding and thus 
the presence of an N-terminal fusion tag may affect bio-
logical activity [15]. Thus, removal of N-terminal tags is 
absolutely required to guarantee functional recombinant 
venom peptides.
The European VENOMICS Project (FP7, n° 278346) is 
a consortium studying animal venoms to develop the use 
of toxins as innovative drugs. VENOMICS aims to estab-
lish a new paradigm in venom science by first exploring 
the peptide content of venoms by transcriptomics and 
proteomics and then by building a large library of bio-
active molecules for drug discovery by high-throughput 
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synthesis and recombinant expression of animal venom 
peptides. For the recombinant production of oxidized 
peptides in E. coli; first, the consortium reproduced and 
benchmarked several production options published in 
the literature and then, after optimization, applied the 
best protocol to the production of 5000 recombinant 
animal venom peptides selected from the VENOMICS 
database. The optimization of the production protocol is 
detailed in this manuscript. The application of this new 
procedure for the production of 5000 toxins is described 
in the accompanying article.
Within this publication, we have examined and opti-
mized gene design, the choice of fusion tag, as well as 
TEV cleavage conditions and recognition site to improve 
the production of oxidized recombinant venom peptides 
in E. coli. The challenge to face was to find the best pro-
tocol that would be amenable to the throughput dictated 
by the VENOMICS objectives; build a peptide library of 
thousands of reticulated animal venom peptides in a mat-
ter of months, where individual optimization of the pro-
duction steps would be impossible.
Overall data reported here suggest that E. coli is an 
effective host to express milligram per litre culture quan-
tities of correctly oxidized recombinant venom peptides 
using high-throughput technologies.
Methods
Design of gene variants encoding venom peptides
For the initial studies, 24 representative venom pep-
tides originating from 21 different animal species 
were selected. The peptides had sizes ranging from 21 
to 84 residues and contained between 2 and 7 disul-
phide bridges (Additional file  1: Table S1). The primary 
sequence of the 24 venom peptides was back-translated 
using a Monte Carlo repeated random sampling algo-
rithm to generate three gene variants per peptide. This 
algorithm selects a codon for each position at a prob-
ability defined in a codon frequency lookup table. The 
lookup table applied to create the three variant designs 
of each gene varied in global codon usage within codons 
used preferentially in highly expressed or average native 
Escherichia coli genes. Other factors considered for gene 
design were GC content, mRNA structure, absence of 
prokaryotic regulatory sequences and contiguous strings 
of more than 5 identical nucleotides, which were set not 
to vary within the different gene variants. Due to the use 
of Monte-Carlo sampling for gene design, all the three 
variants were significantly different in sequence identity 
from each other. The average pairwise DNA sequence 
identity was 79.8% for the 24 datasets. Thus, in the initial 
phase of this work a total of 72 genes were designed (3 
gene variants of 24 peptides), the sequences presented in 
Additional file 1: Table S1.
Gene synthesis, cloning and protein expression/
purification of initial 72 variants
The 72 synthetic gene variants were produced using 
standard procedures [16, 17]. The sequence coding for a 
TEV protease cleavage site (ENLYFQ/G) was engineered 
upstream of each gene. This sequence was identical for all 
72 gene variants. Nucleic acids were synthesised contain-
ing Gateway recombination sites on each extremity. After 
PCR assembly, synthetic genes were directly cloned into 
pDONR201 using Gateway™ BP cloning technology (Inv-
itrogen, USA) [18]. Like for all the other plasmids and 
constructs used in this study, each construct was com-
pletely sequenced in both directions to ensure 100% con-
sistency with the designed sequences. The 72 sequence 
entry clones were recombined using the Gateway™ LR 
cloning technology (Invitrogen, USA) to transfer the 
peptide-coding genes into pETG82A destination vector 
[19]. Destination vector pETG82A contains the sequence 
coding for a DsbC fusion partner, which is located at the 
5′end of the inserted gene. All recombinant peptides 
fused with an N-terminal DsbC fusion tag contain an 
additional internal 6HIS tag for protein purification. Each 
variant plasmid was used to transform E. coli expression 
host strain BL21(DE3) pLys S (Invitrogen, USA). The 
choice of the plasmid and strain used in this experiment 
was based on our previous studies done on reticulated 
peptides [11]. Transformed cells were grown on solid 
media and resulting colonies were used to inoculate 4 mL 
of ZYP-5052 auto-induction medium [20] supplemented 
with 200 µg/mL of ampicillin. All steps were carried out 
in 24 deep-well plates (DW24) following exactly the lab 
standard protocol [11, 21], which is described briefly 
below. ZYP-5052 medium is an auto-inducing buffered 
complex medium. Recombinant protein expression was 
induced following a standardized two-step process. Cells 
were grown at 37 °C to quickly reach the glucose deple-
tion phase just before the induction. After that step (4 h, 
OD600  ~1.5) the temperature was lowered to 17  °C for 
18 h to favour protein folding and soluble protein expres-
sion. Cells were collected by centrifugation, re-suspended 
in 1 mL of lysis buffer (Tris 50 mM, NaCl 300 mM, Imi-
dazole 10 mM, Lysozyme 0.25 mg/mL, pH 8) and recom-
binant proteins purified from crude lysates using an 
automated nickel affinity procedure [8, 9]. Briefly, the 
crude cell lysates were incubated with Sepharose chelat-
ing beads (200 μL with bound Ni2+) and then transferred 
into 96-well filter plates (Macherey-Nagel). The wells 
were washed twice with buffer A (Tris 50  mM, NaCl 
300  mM, Imidazole 50  mM, pH 8). The recombinant 
fusion proteins were eluted from the resin beads with 
500 µL of elution buffer (Tris 50 mM, NaCl 300 mM, Imi-
dazole 250 mM, pH 8) into 96-deep-well plates. All pro-
tein purification steps were automated on a Tecan robot 
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(Switzerland) containing a vacuum manifold. Analysis of 
the purified protein yields was performed on a Labchip 
GXII (Perkin Elmer, USA) microfluidic high throughput 
electrophoresis system. These analyses provided an esti-
mation of the molecular weight, purity and concentra-
tion of the proteins. All the quantitative values given in 
this manuscript are based on the calculation made by the 
Labchip GXII software.
Construction of pHTP‑derivative vectors to express venom 
peptides in E. coli
A collection of 5 novel vectors was constructed based 
on the prokaryotic expression vector pHTP1 (NZYTech, 
Portugal). The DNA sequences encoding a fusion protein 
tag were inserted into pHTP1 plasmid downstream of the 
T7 promoter, such that the protein tags would become 
fused to the N-terminus of the target peptide. DNA 
sequences encoding fusion tags were obtained by gene 
synthesis (see above) and included upstream and down-
stream NcoI restriction sites. Once inserted into pHTP1 
backbone after digestion with NcoI, the five pHTP vec-
tors retained the C-terminal hexa-histidine (6HIS) tags 
for protein purification (Additional file 2: Table S2). The 
five novel tags were based on disulphide-bond isomerase 
C (DsbC) and maltose-binding protein (MBP) [11, 21–28] 
sequences, some of the best tags for producing functional 
venom peptides in E. coli described to date. Thus, vector 
pHTP2 (pHTP-LLDsbC) encodes the sequence of DsbC 
for cytoplasmic expression. In addition, pHTP3 (pHTP-
mutDsbC) express a redox inactive mutant of DsbC while 
in pHTP4 (pHTP-DsbC), the sequence of a signal pep-
tide is included before the DsbC to allow export of the 
recombinant fusion protein to the periplasm. Similar 
vectors were also produced encoding MBP derivatives 
and were termed pHTP5 (pHTP-LLMBP) and pHTP6 
(pHTP-MBP), respectively. The protein sequences of the 
six fusions created for this project are presented in Addi-
tional file  2: Table S2. Schematic representations of the 
fusion proteins expressed from each vector are shown in 
Fig. 3.
Cloning genes encoding 16 venom peptides into 6 pHTP 
vectors
The genes encoding 16 representative animal venom 
peptides were synthesised as described previously with 
a codon usage optimized for expression in E. coli. Seven 
selected peptides are the same as those selected in Addi-
tional file 1: Table S1 (Additional file 3: Table S3, in bold). 
Out of these 16 peptides, 8 were selected for the TEV 
cleavage optimization protocol (Additional file  3: Table 
S3, in italic) including MT7, that was also selected in this 
study as it turned out to be one of the most challeng-
ing target of our previous study [11]. The 16 synthetic 
genes encoding venom peptides were directly cloned 
into pUC57. Upstream and downstream of all 16 genes, 
a 16  bp sequence was engineered to allow cloning into 
vectors of the pHTP-series using the NZYEasy cloning 
protocol (NZYTech, Portugal). Sequence and properties 
of the 16 genes produced here are presented in Addi-
tional file  3: Table S3. The 16 different peptide genes 
were transferred from the pUC57 vector into each one 
of the 6 expression vectors in an experiment consisting 
of 96 cloning reactions. Reactions consisted of 240 ng of 
each linearized vector, 120  ng of the pUC57 derivative 
containing the target peptide gene, 1 μL of enzyme mix 
and 2 μL of 10× reaction buffer. Cloning reactions were 
carried out in 20  μL final volume on a thermal cycler 
programmed as follows: 37  °C for 1 h; 80  °C for 10 min 
and 30  °C for 10  min. The reaction mixtures were used 
to transform DH5α E. coli competent cells. Two colo-
nies were picked for each construct and the presence of 
insert confirmed by PCR using the vector specific T7 and 
pET24a forward and reverse primers, respectively. All 
96 plasmids containing the venom peptide genes were 
sequenced to confirm integrity of the cloned nucleic acid.
Recombinant protein purification and TEV cleavage 
protocol
The 96 recombinant pHTP derivatives were used to 
transform BL21 (DE3) pLysS E. coli cells. Recombinant 
strains were grown in 4  mL of auto-induction medium 
supplemented with kanamycin (50  μg/mL). Recombi-
nant peptides fused with different tags were purified as 
described above.
The TEV clone used in these studies is the TEVSH, 
a kind gift of Dr H. Berglund [29]. The purification of 
the TEVSH was done following the published protocol 
except that the LB medium was replaced by ZYP5052 
(or TB) medium to reach a yield of purified TEVSH up 
to 100  mg/L culture. At the end of the purification, the 
TEVSH was dialyzed into Hepes 20 mM, NaCl 300 mM, 
Glycerol 10% (v/v), pH 7.4 to remove traces of DTT, con-
centrated to 2 mg/mL and stored at −80 °C.
The TEV cleavage protocol used here to remove fusion 
tags from recombinant peptides was described elsewhere 
[9]. In order to simplify the study, based on previous in-
house experiments [8, 9, 11], several parameters were 
kept constant (unless this is specified) for all the TEV 
cleavages; the concentration of purified fusion protein 
(1 mg/mL), a fusion/TEV ratio of 1/10 (w/w), the buffer 
composition, the temperature (30 °C) and the incubation 
period (18 h). The cleavage buffer chosen was the IMAC 
protein elution buffer (Tris 50 mM, NaCl 300 mM, Imida-
zole 250 mM, pH 8) which considerably simplifies down-
stream processing by avoiding the dialysis step to remove 
the imidazole from the buffer prior to the addition of the 
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protease. When necessary, the cleavage buffer was sup-
plemented with fresh DTT (see “Results” section).
Before the cleavage an aliquots (20  µL) of the 96 un-
cleaved samples were blocked with caliper sample buffer 
following the manufacturer protocol. After the 18 h TEV 
cleavage, samples were acidified for 1  h with 5% ACN, 
0.1% formic acid. Precipitated material (TEV protease, 
fusion tags and misfolded peptides) was removed by cen-
trifugation (10 min at 4100×g). Three Aliquots (20 µL) of 
the 96 cleaved samples were collected, two for the mass 
spectrometry analysis and one that was boiled with the 
caliper sample buffer. To check that the cleavage was suc-
cessful and to calculate TEV cleavage yields, these sam-
ples were run side by side with the uncleaved controls 
on the caliper GXII system. The TEV cleavage efficiency 
was calculated using the Labchip quantification software. 
Because proteins below 5  kDa cannot be quantified by 
the software, the cleavage efficiency was only calculated 
by integrating and comparing the disappearance of the 
fusion-peptide species band on the labchip.
Tag removal and mass spectrometry
After TEV cleavage, one aliquot (20 µL) of the 96 cleaved 
samples kept for mass spectrometry were analysed in-
house on a reverse phase C18 column at 37 °C (Hypersil 
GOLD 50 ×  1.0  mm, 1.9  μm, 175 Å, ThermoScientific) 
at a flow rate of 200 μL/min on a UHPLC–MS with elec-
trospray detection (Accela High Speed LC system with 
detector MSQ+  , ThermoScientific, San Jose, CA). The 
gradient slope (solvent A: water, B; acetonitrile, both sol-
vents containing 0.1% formic acid) went from 5 to 40% B 
in 2  min followed by an 80% wash and re-equilibration 
(total time: 6 min). MS acquisition was performed in the 
positive ion mode from m/z 100 to 2000. To confirm cor-
rect peptide molecular weight, the resulting mass spectra 
were de-convoluted using manual calculations. The iso-
topic pattern measured was compared with the theoreti-
cal one determined from the amino acid sequences using 
DataExplorer software (Version 4.9, Applied Biosystems). 
The quantitative calculation of peptide yields were deter-
mined using automatic processing with Xcalibur soft-
ware (ThermoScientific), by OD280 nm measurement and 
peak areas integration. The peptide cleavage and recov-
ery yield calculation was made by comparing the quanti-
ties of peptide present in the initial sample after Nickel 
purification (fusion-His-Toxin band on the caliper), 
given by the caliper GX II software versus the final yield 
of oxidized peptide quantified by the OD280 nm measure-
ment and peak areas integration by the LC system. To 
comfort these results, the second aliquot was sent to our 
VENOMICS collaborator Dr. L. Quinton (University of 
Liège, Belgium) toxin and mass spectrometry specialist 
who confirmed the correct oxydation and good cystein 
connectivity of these known toxins (data no shown). 
More details on the quality control by mass spectrometry 
on the VENOMICS toxins can be found on the accompa-
nying article.
Generation of N‑terminal variants of DNA/RNA‑binding 
protein KIN17
To test the efficacy of TEV protease to cleave peptide 
chains including variations at the C-terminus of the 
consensus recognition site of the enzyme (ENLYFQ/X), 
the gene encoding the C-terminal domain of the DNA/
RNA-binding protein Kin17 (Kin17´) from Homo sapi-
ens was synthetized. PCR was used to create 20 gene 
variants encoding derivatives of the Kin17´ protein with 
20 different N-terminal amino acids at the TEV recog-
nition site. The genes were produced by PCR including 
the reverse primer HSr, 5′-GGGGACCACTTTGTAC 
AAGAAAGCTGGGTCTTATTAAAGTTTAGAGATG 
TCTTCAT-3′ and the forward primers presented in 
Additional file 4: Table S4. Amplified nucleic acids con-
tained Gateway recombination sites on each extrem-
ity. Thus, genes were initially directly cloned into 
pDONR201 using Gateway™ BP cloning technology (Inv-
itrogen, USA). The 20 gene variants were subsequently 
cloned into pDest17 (Invitrogen, USA) using Gateway™ 
LR cloning technology (Invitrogen, USA). Resulting 
expression plasmids encode for Kin17′ derivatives con-
taining an N-terminal 6HIS tag and a TEV recognition 
site combining 20 variations at the residue occupying 
its C-terminal (P1′) position. Primary sequence of both 
proteins and respective genes are presented in Table S4. 
The 20 plasmid derivatives were used to transform BL21 
(DE3) pLysS E. coli cells and recombinant proteins were 
produced, purified and cleaved. The TEV cleavage of the 
20 variants of Kin17 was done in the buffer and condi-
tions selected for the final venom peptide production 
pipeline of the FP7 VENOMICS Project.
Results
Codon usage of venom peptide‑coding genes cause 
expression differences
Twenty-four genes of various lengths encoding venom 
peptides from different species and containing different 
numbers of disulphide bridges were chosen to explore 
the effects of codon usage on soluble levels of puri-
fied proteins. These genes encode venom peptides that 
are evolutionarily, structurally and functionally diverse. 
The experiment aims to evaluate if subtle changes in 
codon usage can affect levels of recombinant peptide 
expression in E. coli. Three variants of each gene were 
initially designed by back-translating venom peptide 
sequences using a Monte Carlo repeated random sam-
pling algorithm to select codons probabilistically from 
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codon frequency lookup tables. The codon usage of the 
72 devised genes (3 variants of 24 genes) is presented in 
Additional file 5: Table S5 and reflects the codon usage of 
Escherichia coli genes expressed at moderate to high lev-
els. However, created gene variants incorporated changes 
in DNA primary sequences which reflect the random 
sampling of codon selection and the overall freedom 
permitted by the algorithm used for gene design. Thus, 
the average pairwise DNA sequence identity was 79.8% 
within the three variants of the 24 datasets.
The 72 genes were synthesized and cloned using the 
Gateway system into pETG82A prokaryotic expression 
vector under the control of a T7 promoter and in fusion 
with the gene encoding the DsbC fusion tag for cytoplas-
mic expression. E. coli BL21 (DE3) pLys S were trans-
formed with the 72 plasmids and grown in auto-induction 
media. Fusion proteins were purified and protein integ-
rity and yield measured by Caliper Labchip GXII analysis 
(Fig. 1a). Depending on the peptide of interest, the puri-
fied fractions run on the Caliper Labchip GXII mainly as 
a single band (peptides 1, 2, 3, 4…) or as a double band 
(5, 8, 16, 18…). The single band represents the good pro-
tein population (His-DsbC-peptide) while the lower band 
(around 29  kDa) corresponds to the His-DsbC protein 
alone after truncation/degradation of the target peptide. 
This lower band probably indicates that there is a portion 
of the peptide population that was not properly folded 
and was degraded during the expression or purification 
processes. The protein concentration depicted in Fig. 1b 
has been calculated by integrating only the His-DsbC-
peptide band using the Caliper software. The data, pre-
sented in Fig.  1b, revealed that yields of purified fusion 
protein varied from  ∼1  mg/L (for fusion protein 14) to 
above 100 mg/L (for fusion proteins 4, 5, 8, 9, 10, 18 and 
24). For the vast majority of targets (19/24) the quanti-
ties of fusion protein purified would allow the purifica-
tion of milligram scale of target peptide per litre of culture 
(assuming a cleavage and purification yield around 100%) 
while for the remaining five peptides (6, 7, 11, 13 and 14) a 
larger volume of culture would be needed.
The correlation between primary sequence of gene 
variants and properties that have been suggested to affect 
expression was analysed. Deleterious motifs, such as 
5′ mRNA secondary structures could not have affected 
levels of expression as venom genes were all fused to 
the same 5′-prime sequence, which encodes the protein 
fusion tag. There was no correlation between protein 
expression and number of disulphide bridges, peptide 
size, CAI value and GC content (data not shown). This 
suggests that differences in gene expression were deter-
mined by other sequence related properties in particu-
lar by codon usage. In order to investigate how changes 
in codon usage affected levels of recombinant peptides, 
the relation between protein yields of the low, medium 
and high expresser variants within the 24 data sets were 
compared. Fusion proteins expressing at lower levels, 
which concern peptides 6, 7, 11, 13 and 14 (Fig. 1), were 
excluded from the analysis. The data revealed that pro-
tein yields of the high, medium and lower expresser vari-
ants of the peptides analysed were significantly different. 
Thus, lower expressers produced on average 65.1 mg/L of 
recombinant fusion protein, while fusion protein yields 
of higher expressers were, on average, of 87.55  mg/L 
(Fig.  1b). These differences are significantly different 
(p = 0.01).
To evaluate what differences in codon usage could 
explain observed differences in protein expression, the 
codon usage of low and high expressing variants was 
compared. Codon usage tables including genes con-
taining the fusion tag are presented in Table S6. Major 
differences in codon usage concern in particular one 
amino acid, cysteine, although slight changes were also 
observed for other residues in particular arginine, aspara-
gine, glutamate, histidine, isoleucine, phenylalanine and 
serine. Summary codon usage data for these 8 amino 
acids is shown in Table  1. The codon bias observed for 
low expressing genes revealed a preference for Cys-
TGC codon while in high expressing genes Cys-TGT is 
favoured. In addition, in low expressing genes Cys-TGC 
is used 1.38 times more frequently than Cys-TGT, while 
in high expressing genes Cys-TGT is only used 1.04 times 
more often than Cys-TGC. Although other factors may 
eventually be operating, this observation suggests that 
high expression of genes encoding peptides requires a 
similar contribution of both Cys-TGC and Cys-TGT 
codons, suggesting that a higher percentage of one codon 
compared to the other will affect expression. Cysteine 
codon usage in E. coli also points to a more balanced uti-
lization of the two codons (Table 1). To investigate factors 
that may explain this observation, amino acid frequency 
in E. coli genes and within the 24 venom peptides selected 
for this study and their associated fusion proteins were 
compared. The data, presented in Fig.  2, revealed that 
cysteine is ~12.5 and 3.5 times more frequent in venom 
peptides (14.3%) and in the recombinant fusion proteins 
(4.1%), respectively, than in E. coli (1.16%). Thus, the data 
suggest that expression of venom peptides at high levels 
is favoured by the presence of the two cysteine codons at 
similar frequency in synthetic genes. This should avoid 
the depletion of one codon when genes are expressed at 
very high levels.
Levels of expression of venom peptides are affected by the 
fusion tag
Five novel vectors for recombinant protein expression 
in E. coli were constructed by inserting different fusion 
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tags into the pHTP1 backbone. All fusion tags are to be 
inserted at the N-terminus of the recombinant peptides 
(Fig.  3). Two of the vectors encode fusion partners that 
contain a signal peptide to target venom peptide expres-
sion into the periplasm (pHTP4, pHTP6). The remain-
ing fusion tags will lead to cytoplasmic recombinant 
protein expression (Fig.  3). In all cases a 6HIS tag was 
introduced to enable the downstream purification of the 
fusion proteins using immobilized-nickel affinity chro-
matography. A TEV (tobacco etch virus) protease cleav-
age site (ENLYFQ/G) was introduced in all synthetic 
genes to enable removal of the fusion partner. In addition 
to the 6HIS affinity tag alone (pHTP1) the 5 novel vec-
tors include the disulphide isomerase DsbC or maltose 
binding protein (MBP). An inactive mutant derivative 
of DsbC was produced to try to discriminate the roles of 
Fig. 1 Yields of 24 purified recombinant fusion proteins originated from 3 different gene designs. a Virtual gel showing the expression levels of 
24 recombinant peptides obtained from gene design A, B and C that were purified through IMAC and evaluated using the Labchip GXII (Caliper, 
USA). b Comparison of expression levels of variant A (blue), variant B (orange) and variant C (grey) of the 24 recombinant peptides. On the right are 
representations of the means for high, medium and low expressing variants calculated for the 16 fusion peptides produced at higher yields. Means 
without a common letter differ at P < 0.01
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DsbC in passive solubilisation (relating to fusion protein 
yield) and redox activity (relating to the yield of correctly 
folded target peptide). The schematic representation of 
all vectors use in this study is presented in Fig. 3.
Sixteen well characterized venom peptides (including 7 
that were part of the codon usage experiment described 
above) with different origins and representing different 
folds and cysteine bond patterns were selected for this 
study (see Table S3). The 16 synthetic genes were inserted 
into the six different expression vectors (see Table S2 
and Fig.  3) generating a total of 96 recombinant plas-
mids. The 96 constructs were transformed in BL21 (DE3) 
pLysS. Recombinant E. coli strains were grown in auto-
induction media to obtain high cell densities. After nickel 
affinity purification, systematic analysis of the Labchip 
GXII electropherograms was performed to determine 
the concentration of the purified proteins and compare 
the apparent molecular weight of the purified fusion pro-
teins with their expected theoretical molecular weight. 
Data, presented in Fig.  4, revealed that the 16 peptides 
can indeed be produced using a fusion tag. Depending 
on the peptide and the fusion used, the levels of purified 
fusion proteins varied from zero (mostly when peptides 
were cloned in pHTP1) to more than 300 mg of purified 
fusion protein per litre of culture. Overall, smaller pep-
tides seemed to be easier to produce than larger ones but 
there are several counter-examples (like T16 which is 
the largest peptide of the study). For peptides 2, 4, 7, 8, 
9, 14 and 15, different vectors seemed to be appropriate 
for fusion protein expression but in most cases (13 out 
of 16) vector pHTP4 (DsbC) outperformed all other vec-
tors. In contrast, without exception, soluble expression 
with 6HIS tag alone was always very low. The presence 
of the signal peptide lead to higher levels of expression 
for DsbC in all cases (pHTP4 versus pHTP2) doubling on 
average the amount of expressed fusion protein. For MBP 
(pHTP6 versus pHTP5) its presence gives a similar trend 
(10/16). For the other six peptides, either the cytoplasmic 
level was similar (1, 5, 11) or even significantly better (2, 
7, 14). Overall out of 16 peptides, when the periplasmic 
DsbC was not the best option, it was the cytoplasmic (for 
peptides 2 and 14) or periplasmic (peptide 4) MBP that 
were the best options. Finally, the inactivation of DsbC 
biological function had no effect in expression levels of 
Table 1 Codon usage of genes encoding high and low expresser variants encoding either venom peptides or the respec-
tive fusion protein
AA Codon Fc, HE, toxins Fc, LE, toxins Fc, HE, fusion Fc, LE, fusion Fc, E. coli
Arg AGA 0 0 0 0 0.07
Arg AGG 0 0 0.17 0.17 0.04
Arg CGA 0 0 0 0 0.07
Arg CGC 0.38 0.44 0.35 0.39 0.36
Arg CGG 0 0 0 0 0.11
Arg CGT 0.63 0.56 0.48 0.45 0.36
Asn AAC 0.55 0.64 0.47 0.49 0.51
Asn AAT 0.45 0.36 0.53 0.51 0.49
Cys TGC 0.49 0.58 0.49 0.56 0.54
Cys TGT 0.51 0.42 0.51 0.44 0.46
Glu GAA 0.84 0.76 0.62 0.60 0.68
Glu GAG 0.16 0.24 0.38 0.40 0.32
His CAC 0.26 0.48 0.33 0.35 0.43
His CAT 0.74 0.52 0.67 0.65 0.57
Ile ATA 0 0 0 0 0.11
Ile ATC 0.49 0.32 0.57 0.54 0.39
Ile ATT 0.51 0.68 0.43 0.46 0.49
Phe TTC 0.28 0.44 0.14 0.16 0.42
Phe TTT 0.72 0.56 0.86 0.84 0.58
Ser AGC 0.51 0.40 0.67 0.65 0.25
Ser AGT 0.09 0.16 0.11 0.13 0.16
Ser TCA 0.05 0.05 0.11 0.11 0.14
Ser TCC 0.11 0.16 0.07 0.08 0.17
Ser TCG 0.13 0.15 0.02 0.02 0.14
Ser TCT 0.11 0.07 0.02 0.01 0.15
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venom peptide fusion proteins, as expression of pHTP2 
and pHTP3 were, in general, very similar.
Fusion cleavage, peptide yield and correct oxidation 
state is mainly affected by the fusion partner and DTT 
concentration in TEV cleavage buffer
Optimal TEV cleavage conditions to release target pep-
tides from fusion tags are affected by several parameters 
including enzyme/substrate ratio, buffer composition, 
incubation period and temperature. To investigate which 
conditions would lead to the best yield of folded venom 
peptides, eight peptides were selected from the list of 16 
produced in the previous experiment (See Additional 
file 3: Table S3, peptides in italic, and Fig. 4, peptides in 
boxes). Because the DsbC fusion partner outperformed 
other tags in terms of fusion protein yields and general 
applicability, these constructs were selected for the TEV 
cleavage optimisation study. The only parameter that 
turned out to be critical and therefore was was fine-
tuned in this experiment was the DTT concentration (0, 
0.1, 0.5 and 2  mM DTT) present in the cleavage buffer. 
Indeed, while the TEV protease requires reducing con-
ditions for optimum cleavage, an excessive concentra-
tion of DTT could lead to the reduction of the peptides’ 
intra-disulphide bridges and loss of folding and biological 
activity.
After an 18 h incubation period, an aliquot of the TEV-
fusion peptide mixture was acidified. A fraction (“before” 
versus “after” TEV cleavage) was loaded on the Caliper to 
determine the cleavage efficiency and a sample was ana-
lysed on the LC–MS to quantify the toxin and confirm its 
correct oxidation state. Cleavage efficiency, mass analy-
sis and peptide yields are summarized in Fig. 5. Cleavage 
occurred in the 32 conditions tested in the assay (ranging 
from 30 to 100% efficiency). As expected, cleavage was 
not complete in the absence of DTT and complete with 
the highest concentration of DTT. Out of eight peptides, 
seven could be detected oxidized in mg quantities per 
litre of culture. From the 32 samples, 19 gave the correct 
oxidized mass on the LC–MS with various yields depend-
ing on the DTT concentration during cleavage. For the 
13 samples left, no peaks were detected on the LC–MS. 
From the seven peptides correctly detected in various 
DTT concentration, four gave the highest recovery in 
0.1 mM DTT, while two needed no DTT and one needed 
0.5  mM DTT for optimum recovery (Fig.  5, in bold). A 
DTT concentration of 0.1  mM appeared to be the best 
compromise to be kept for the following experiments and 
Fig. 2 Comparison of amino acid frequency in Escherichia coli with the frequency of each amino acid in recombinant peptides analysed in this 
study. Percentage of abundance of each amino acid in E. coli is displayed in blue. In red, frequency of the same amino acid in venom peptide coding 
genes analysed in this study excluding the sequence encoding the fusion tag. A dramatic increase in the percentage of the amino acid cysteine is 
observed in venom peptides and this is highlighted by a red arrow
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Fig. 3 Schematic representation of the expression vectors that contain fusion tags with and without redox properties, which were used for 
cytoplasmic and periplasmic expression of venom peptides in Escherichia coli. All vectors include a T7 promoter, a ribosome binding site (rbs), a lac 
operator, a 6HIS tag for nickel affinity purification and a Tobacco Etch Virus (TEV) protease cleavage site. The 6HIS tag is N-terminal for pHTP1 vector 
(a) and internal for expression vectors including fusion tags (b). pHTP4 (DsbC) and pHTP6 (MBP) carry fusion tags containing a signal peptide (rep-
resented in crossed green lines) to target exportation of the fusion protein to the periplasm of E. coli cells. The inactive DsbC fusion partner, which 
contains two mutations at the catalytic site (C100A and C103A), was inserted into pHTP3 (LLmutDsbC)
Fig. 4 Yields of 96 purified recombinant fusion proteins originating from 16 different animal venom peptides in 6 fusions. Peptides are organized by 
increasing mass. Each fusion is represented by a color code. Yield is expressed in milligram of fusion per litre of culture. Fusion proteins were purified 
through IMAC and evaluated using the Labchip GXII (Caliper, USA). Peptides depicted in boxes were selected for the TEV cleavage experiment (see 
Fig. 5)
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the production pipeline of the VENOMICS Project. Ali-
quots of the 7 peptides were concentrated to 2 and 4 mg/
mL and subjected to the same experiment with 0.1 mM 
DTT to confirm that cleavage would be possible in these 
conditions. On average, the efficiency dropped by 20% 
but occurred in all cases (data not shown).
Following the optimization of cleavage conditions, 
the 96 purified fusion proteins (16 in 6 vectors, see 
Fig.  4) were cleaved in the presence of 0.1  mM DTT at 
the concentration of the purified pools (ranging mostly 
from 0.2 to 2  mg/mL) following the protocol described 
above. After cleavage and acidification an aliquot of the 
96 samples was analysed by LC–MS to confirm the cor-
rect molecular mass, yield and the oxidation state of 
the final recombinant venom peptide. When detected, 
the 96 recombinant peptides had molecular masses in 
agreement with the expected masses given fully oxi-
dized cysteine residues (See accompanying article for 
more details on the mass Spectrometry analysis); the 
reduced forms of the proteins were never detected (data 
not shown), probably due to precipitation of incorrectly 
oxidized peptides during cleavage and acidification steps. 
The final yield for the 96 constructs, presented in Fig. 6, 
was expressed as absolute peptide final yield in mg/L cul-
ture or normalized to 100% for each peptide relative to 
the vector used for expression. The data (Fig. 6) revealed 
that all 16 peptides under study could be produced 
recombinantly, but at different levels. Similar to the yield 
obtained for the fusion variants (Fig. 4), a general trend 
suggests that the shorter peptides are easier to produce 
than the longer ones. The final venom peptide yield varied 
greatly with a 50-fold difference between the worst case 
(0.3 mg/L, T10 in pHTP6) and the best case (17.6 mg/L, 
T1 in pHTP4). The dataset also revealed that there was 
a significant drop in yields following fusion tag cleavage. 
This is probably due to the harsh recovery condition after 
cleavage (acidification in 5% acetonitrile, 0.1% formic 
acid) where on top of the TEV protease, any cleaved mis-
folded peptide precipitates. As expected from the fusion 
yields, even if recovery is high, peptides produced with 
pHTP1 gave the lowest quantities of peptides overall 
(0.4 mg/L on average, with a maximum of 1.9 mg/L for 
T8). In contrast, peptides produced with pHTP4 (DsbC) 
reached the best final peptide yields for 11 of 16 peptides, 
and of these (with the exception of T11) yields were more 
than 2 mg/L for each peptide (4.6 mg/L average). Over-
all, DsbC fusions (for either periplasmic or cytoplasmic 
expression) successfully produced 14 out of 16 venom 
peptides. Furthermore, one peptide (T7) could only be 
produced in the periplasm, using the DsbC fusion part-
ner, from the pHTP4 vector. For peptides produced pref-
erentially from other vectors (T10, 12, 13, 14, 16), yields 
do not surpass 2 mg/L, highlighting the robust expression 
from the pHTP4 vector. For these five peptides, highest 
yields were achieved with cytoplasmic expression and 
a DsbC fusion partner in three cases, followed by peri-
plasmic expression with the MBP fusion partner in two 
cases. In most cases (except T13,T14 and T16), the fusion 
exported to the periplasm (for either DsbC or MBP) out-
performed its cytoplasmic equivalent, indicating that at 
least part of the folding could occur in the periplasm and 
part could occur ex vivo during the purification. A strik-
ing demonstration that DsbC (and probably MBP) acts, 
in part, as a passive solubilising agent inside the bacteria 
Fig. 5 TEV cleavage efficacy in various concentrations of DTT. The cleavage efficiency represents the percentage of fusion cleaved for each DTT 
concentration (0–2 mM) quantified by Labchip GXII (Caliper, USA) and depicted in percentages. The correct oxidation state of the purified peptide 
was confirmed by LC–MS (green mass corresponds to oxidized peptide, red no peptide detected). When a correct mass is detected the yield of 
peptide per litre of culture quantified by integration of the LC peaks is indicated in the well
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is the fact that while the fusion yields between the DsbC 
and the mutated DsbC constructs were very similar for 
most peptides (Fig.  4), after cleavage and recovery, the 
overall yield of active peptide is on average three times 
higher in the case of the redox-active DsbC fusion than 
with its mutated DsbC counterpart. The detail of the 
quantitative values has been summarized in Additional 
file 7: Table S7.
The nature of the C‑terminal (P1′) residue of the TEV 
cleavage site does not significantly affect cleavage efficacy
The N-terminus of some venom peptides can contribute 
to their receptor binding sites. Thus, it is possible that 
the introduction of a single extra residue at the N-termi-
nus of the peptide may affect its biological activity [15]. 
The canonical TEV protease recognition site requires a 
Gly or Ser residue at its C-terminus (P1′ position), leav-
ing a non-native Ser or Gly residue at the N-terminus 
of the target peptide after tag removal. A previous study 
[30] suggested that, with the exception of proline, all the 
amino acid side-chains could be accommodated in the 
P1′ position of a TEV protease recognition site with lit-
tle impact on the efficiency of processing. The analysis 
was, however, performed in optimal TEV buffer condi-
tions. In order to be time-efficient, the venom peptide 
production pipeline can not accommodate additional 
steps such as buffer exchange into optimal TEV condi-
tions. Thus, the capacity of TEV protease to act in the 
IMAC elution buffer (Tris 50  mM, NaCl 300  mM, Imi-
dazole 250  mM, DTT 0.1  mM, pH8) a non-optimum 
buffer for TEV proteolysis, was investigated. The TEVSH 
protease used in this study [29] was selected because it 
Fig. 6 Yields of 96 purified recombinant peptides after tag removal. Peptides are organized by increasing mass. Each original fusion tag used to 
express each peptide is represented by a color code (identical to Fig. 4). Yield is in milligram of oxidized peptide per litre of culture. The correct oxida-
tion state of the purified peptide was confirmed by LC–MS and the yield of peptide per litre of culture quantified by integration of the LC peaks. a 
Concentration in mg/L of culture. b Yield of peptide is presented in percentage relative to the best condition to better visualize the low expressing 
peptides. Peptides depicted in boxes were selected for the TEV cleavage experiment (Fig. 5)
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is easy to overproduce and purify in E. coli at very high 
quantities (up to 100 mg/L culture). However, the cleav-
age specificity of this recombinant derivative of TEV 
protease remains unknown, in particular when various 
amino acids occupy the P1′ position of its recognition 
site (Dr H. Berglund, personal communication). Thus, to 
explore the activity of this TEVSH protease in non-opti-
mal conditions and when the P1′ position of the protease 
recognition site is varied, 20 test-cleavage fusion protein 
sequences were produced. Each fusion protein contained 
an N-terminal 6HIS tag, an internal TEV recognition 
sequence, each containing a different amino acid at the 
P1´ position, fused C-terminally to a truncated form of 
the DNA/RNA-binding protein Kin17 from Homo sapi-
ens. Proteins were purified and subjected to TEV pro-
tease cleavage in the same conditions as those used to 
cleave the 96 fusion tags (see above). The data, presented 
in Fig.  7, confirm previous data collected [30] and sug-
gest that, with the exception of proline (the probability of 
having a proline in position 1 of naturally-sourced venom 
peptides is low), all other residues can be accommodated 
at the P1′ position of the TEV protease recognition site 
while retaining some cleavage activity. However, consid-
eration should be given to peptides with an N-terminal 
Trp, Thr, Leu, Glu, Arg, Asp, Val or Ile, where cleavage 
efficiency dips to 60% or less. In these cases a compro-
mise between cleavage efficiency/production yield may 
need to be reached, depending on how well the peptide 
expresses.
Note that in contrast to venom peptides, Kin17 does 
not contain cysteine residues. Thus, the successful cleav-
age yield when a cysteine residues is in position 1 (86%) 
obtained with Kin17 needs to be confirmed for the cases 
of peptides with a cysteine in position 1 that would prob-
ably be involved in a disulphide bridge in the native 
protein.
Discussion
Today de novo gene synthesis is replacing the classic 
cloning approaches for the construction of transgenes 
and thus it is critical to develop effective gene design 
algorithms that could sustain high levels of heterolo-
gous gene expression [31]. Effective design methods 
may require attending to particular properties of dif-
ferent protein families. Thus, the intrinsic abundance 
of cysteine residues in venom peptides is potentially a 
critical factor that may affect the recombinant expres-
sion of such peptides. Here, by designing and synthesiz-
ing 72 individual genes encoding 24 different peptides, 
nucleic acid sequence differences affecting the levels of 
soluble expression of venom peptides were identified. 
Highly expressing gene variants produced up to twice 
the levels of recombinant protein when compared with 
low expressing ones. Factors affecting expression levels 
were identified by comparing the codon usage of high 
and low expressing variants. The data revealed that most 
of the variation in expression can be explained, primar-
ily, by differences in the frequency of cysteine codons but 
Fig. 7 TEV protease cleavage efficiency of Kin17 with 20 different amino acids located at position P1′. The amino acids are organized from the easi-
est to the most difficult ones to cleave. Values are in percentages
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also, at a lower level, for arginine and isoleucine. Thus, 
data presented here reveal that high levels of expres-
sion of venom peptides require a similar usage of the 
two cysteine codons Cys-TGT and Cys-TGC. It is now 
well established that high translation rates contribute to 
deplete the cellular translational machinery [32]. Consid-
ering the levels of expression of the heterologous proteins 
reported in this study we estimate that between 25 and 
40% of the total proteins produced by the bacterial cell 
comprise recombinant fusion polypeptides. Overexpres-
sion of recombinant genes in E. coli leads to a significant 
change in the amino acids being used for protein synthe-
sis in favour of the recombinant protein. In the particu-
lar case of venom peptides, cysteine is a highly frequent 
residue being around four times more frequent in the 
recombinant fusion genes than in regular E. coli genes. 
Thus recombinant E. coli strains expressing venom pep-
tides at high levels will require a similar usage of both 
cysteine codons most likely to avoid depletion of one 
relative to the other. Thus if one codon was present in 
higher frequencies then this will be more easily depleted 
within the cell and will become the limiting codon for 
rate of gene synthesis. Thus, the data suggests that codon 
usage is indeed one of the key determinants of expression 
yield. Regardless of the mechanism by which codon bias 
affects expression, systematic analysis of the relationship 
between gene sequences and expression will be a power-
ful tool to refine our design algorithms, both for E. coli 
and other expression hosts.
Data presented here revealed that the best way to 
express high yields of folded active animal venom pep-
tides is their expression in the periplasm of E. coli. One 
excellent example of the production potential using peri-
plasmic expression is the snake venom peptide, MT7 
(peptide 6 in this study), containing 4 disulphide bonds. 
MT7 was previously expressed using DsbC as a fusion 
partner in the cytoplasm of E. coli [11]. While cytoplas-
mic expression achieved high yields of the DsbC fusion 
protein, after cleavage the peptide could only be purified 
to a yield of 0.007  mg/L culture. Here, by exporting the 
fusion protein to the periplasm, the yield of soluble, oxi-
dized MT7 was increased 500-fold (to 3.9 mg/L culture). 
Note that for the cytoplasmic expression of MT7 with 
a DsbC fusion (the equivalent of the constructs of MT7 
used in the previous study), most parameters have been 
modified between both studies; i.e. codon usage, vector 
backbone, culture and cleavage conditions… These modi-
fications alone increased dramatically the yield of MT7 
compared to our previous study stressing out that every 
steps of the optimized protocol detailed in this study can 
have a drastic impact on the final yield of oxidized pep-
tides. In this study, DsbC was found to be a much more 
efficient fusion partner to express venom peptides in the 
periplasm of E. coli than MBP. The encouraging results 
obtained with DsbC may derive from its excellent solubi-
lisation potential but, more importantly, from its isomer-
ase and chaperonin activities (which MBP lacks) that may 
promote the folding of venom peptides. In the cytoplas-
mic compartment, the redox-inactive tags used (an inac-
tive mutant derivative of DsbC) lead to the production 
of similar yields of recombinant peptides as the wild type 
DsbC. This suggests that redox properties of the fusion 
tag do not affect solubility and folding of animal venom 
peptides during the expression in the cytoplasm of E. 
coli and therefore confirm that oxidation occurs, primar-
ily, ex vivo [8]. During the production and purification of 
the proteins, DsbC is improving the solubility of venom 
peptides rather than assisting the peptides to reach their 
native oxidized form. Nevertheless, during cleavage and 
in the presence of DTT, DsbC probably also acts as an 
isomerase as the yield of peptide varies greatly depending 
on the DTT concentration. Additionally, peptide yields 
from the inactive mutant derivative of DsbC are much 
lower than the two other redox-active DsbC constructs. 
By using the DsbC fusion partner we were able to generate 
high yields of folded, putatively biologically active, venom 
peptides in the periplasm of E. coli. Mass spectrometry 
(coupled with liquid chromatography) not only confirmed 
the exact oxidized mass of all species, but also the cor-
rect connections of the disulphide bridges within the 16 
toxins of this study. In the case of MT7, where an activity 
test was available, the activity of the purified peptide was 
confirmed. Data presented here, using TEV variant pro-
tein TEVSH, a highly soluble TEV mutant, confirmed that 
all residues (except proline) could be accommodated in 
the P1′ position with little or no impact on the efficiency 
of processing, even in a non-optimized cleavage condi-
tion. Therefore, the removal of the associated fusion tag 
with TEV protease (using the shortened recognition site: 
ENLYFQ only) could effectively produce a venom peptide 
with exactly the same sequence properties and biological 
activity as that of non-recombinant molecules.
While the scope of this study was to identify the best 
unique protocol to produce with a high-throughput pipe-
line correctly oxidized toxins in E. coli, we believe that 
this work could be of use for a wider community. The 
results shed light, for scientists working on a more lim-
ited number of toxins, on the parameters that could be 
explored in the case that our best protocol wouldn’t be 
successful on their targets. As demonstrated in the arti-
cle, the main factors affecting the results are the choice 
of codon usage (if the genes have to be synthetized), 
the choice of fusion tags (a good alternative to periplas-
mic DsbC could be periplasmic MBP or the cytoplasmic 
DsbC or MBP) and finally, sometimes really crucial, the 
concentration of DTT in the TEV cleavage buffer.
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Conclusions
There is an urgent need to develop effective methods to 
express large libraries of recombinant disulphide-rich 
peptides, whether sourced from animal venoms or artifi-
cial banks, which could be applied in innovative screening 
platforms for the discovery of novel therapeutics. E. coli is 
a highly robust heterologous host but it displays substantial 
limitations for the production of eukaryotic proteins with 
multiple disulphide bridges, furthermore when thousands 
of peptides are in the scope of the project. Here we have 
analysed how to modulate the levels of expression, solubil-
ity and oxidation of animal venom peptides produced in 
bacteria. This report shows that under optimized condi-
tions E. coli is a pertinent host for the expression of bio-
logically active animal venom peptides even using a single 
protocol to produce peptides with variable length, fold and 
cysteine pattern. Genes encoding venom peptides that are 
expressed at higher levels in E. coli present a codon usage 
that suggest a similar representation of the two Cys codons. 
This study demonstrates that the expression of venom pep-
tides in the bacterial periplasm with the help of a DsbC 
fusion is one of the best options to purify milligram yields 
of active peptides, although the data suggest that peptide 
folding by DsbC occurs mainly ex  vivo. Finally, with the 
exception of Pro, TEV protease can effectively tolerate any 
of the N-terminal amino acids located in venom peptides, 
suggesting that retention of the native peptide N-terminus 
is compatible with an effective protease cleavage.
The findings reported here have been applied to the 
construction of a high-throughput platform for the 
expression of venom peptides in E. coli, and the produc-
tion of the largest bank of animal venom peptides known, 
under the VENOMICS Project, and is reported in the 
accompanying paper.
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